JAK2 and acute lymphoblastic leukemia: In addition, PAX5 fusions, except PAX5::JAK2 and PAX5::ZCCHC7, are observed in over 30% of PAX5alt B-ALL, a recently reported subtype defined by various PAX5 alterations and a distinct gene expression profile (16).